AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5

Ignalis-M IR 50/500 Tablet

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Ignalis-M IR 50/500 Tablet

Diabetic patients with type 2 mellitus find effective blood glucose management with the dual-action Ignalis-M IR 50/500 Tablet. This combination medication mitigates severe diabetic complications like vision impairment and kidney disease, potentially lowering heart attack and stroke risks. Ignalis-M IR 50/500 Tablets can be a standalone treatment or used alongside other diabetes therapies. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is personalized based on individual health, blood sugar readings, and current medications. Consuming it with food minimizes gastrointestinal distress. Consistent daily use at the same time maximizes effectiveness; discontinuation requires medical consultation. Adhering to your doctor's dietary and exercise plan is crucial for successful diabetes management. Lifestyle choices significantly influence blood sugar control. Common side effects include nausea, vomiting, diarrhea, stomach upset, headache, and sore throat. Hypoglycemia is a potential side effect, particularly when used with insulin or sulfonylurea, requiring awareness of symptoms and management strategies. This medication isn't universally suitable. Prior to starting, inform your doctor of any history of kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption. Pregnant or lactating individuals should seek medical advice. Interaction with other medications is possible; disclose all medications to your physician to ensure safety. Alcohol should be limited due to its potential to reduce blood glucose. Kidney function and blood sugar levels will be monitored by your doctor before, during, and after treatment.

Uses of Ignalis-M IR 50/500 Tablet

Managing Type 2 Diabetes

Major Benefits of Ignalis-M IR 50/500 Tablet:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Ignalis-M IR 50/500 Tablet should be administered with a meal.

Common Side effects of Ignalis-M IR 50/500 Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Ignalis-M IR 50/500 Tablet:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment period. Swallow the Ignalis-M IR 50/500 Tablet whole; avoid chewing, crushing, or breaking it. Administer this medication with a meal.

How Ignalis-M IR 50/500 Tablet works:

Ignalis-M IR 50/500 tablets contain sitagliptin and metformin, working synergistically to manage blood glucose. Sitagliptin enhances insulin secretion from the pancreas, improves insulin utilization, and diminishes hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and increases insulin sensitivity. This dual action leads to improved glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Ignalis-M IR 50/500 Tablet and alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Ignalis-M IR 50/500 tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the potential advantages against any risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Ignalis-M IR 50/500 Tablets while breastfeeding is likely inadvisable. Available human data indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Ignalis-M IR 50/500 Tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates the use of Ignalis-M IR 50/500 Tablets. Physician consultation is essential. Regular kidney function monitoring is recommended during treatment.

LiverLiverUNSAFE

Patients with liver conditions should likely avoid Ignalis-M IR 50/500 Tablets due to potential safety concerns. Medical advice is recommended.

What if you forget to take Ignalis-M IR 50/500 Tablet :

Forgetting to take your Ignalis-M IR 50/500 Tablet? Take it immediately if you remember. But, if your next dose is nearly due, omit the missed one and resume your usual dosing pattern. Never take a double dose.

Facts to Know About Ignalis-M IR 50/500 Tablet

LabelValue
Developing Habits No.
Type of Therapy Diabetes Management

FAQs on Ignalis-M IR 50/500 Tablet

Ignalis-M IR 50/500 tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with a healthy diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This combination is unsuitable for individuals under 18.
Prolonged Ignalis-M IR 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Ignalis-M IR 50/500 Tablets may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Patients allergic to Ignalis-M IR 50/500 Tablet components or excipients should not use it. Its use is contraindicated in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Ignalis-M IR 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication safely and ensure it's inaccessible to children, pets, and others.
Yes, Ignalis-M IR 50/500 Tablets can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid. Also known as metformin-associated lactic acidosis (MALA), this rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin immediately and seek medical attention.
Ignalis-M IR 50/500 tablets combine sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Ignalis-M IR 50/500 Tablets may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with allergies to Ignalis-M IR 50/500 Tablet components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis, should not use this medication.
Combining Ignalis-M IR 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA when associated with metformin), is a potential side effect of Ignalis-M IR 50/500 Tablets. This rare complication is reason for caution in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms can include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged use of Ignalis-M IR 50/500 Tablets can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifested as numbness, tingling in extremities, weakness, and balance problems), and urinary or cognitive issues. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Ignalis-M IR 50/500 tablets combine sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18 years of age.
Ignalis-M IR 50/500 Tablets may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients allergic to Ignalis-M IR 50/500 Tablet components or excipients should not use it. Similarly, its use is contraindicated in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Ignalis-M IR 50/500 Tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Yes, Ignalis-M IR 50/500 Tablets can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare side effect is a reason to avoid metformin in patients with kidney disease, older adults, or those who consume large amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Ignalis-M IR 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and urinary issues), and cognitive changes (including balance problems). To mitigate these risks, supplemental vitamin B12 is recommended annually by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication. Keep it out of reach of children, pets, and others.
Ignalis-M IR 50/500 Table...
82
MRP 95
13% off